Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGN NASDAQ:BBNX NYSE:ELMD NASDAQ:SIBN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$15.98+3.8%$13.58$9.22▼$21.00$735.29M1.031.28 million shs1.05 million shsBBNXBeta Bionics$20.20+0.5%$15.60$8.89▼$24.50$878.09MN/A558,901 shs539,151 shsELMDElectromed$24.47-1.8%$20.16$16.58▼$35.56$207.98M0.5483,934 shs87,111 shsSIBNSiBone$16.29-0.4%$16.88$11.70▼$20.05$702.77M0.81326,750 shs240,114 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+3.77%-0.99%+16.22%+46.34%+22.36%BBNXBeta Bionics+0.50%+7.22%+32.89%+5.87%+2,019,999,900.00%ELMDElectromed-1.77%-1.05%+32.77%+16.80%+46.70%SIBNSiBone-0.37%-2.28%-0.73%-13.81%+0.18%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$15.98+3.8%$13.58$9.22▼$21.00$735.29M1.031.28 million shs1.05 million shsBBNXBeta Bionics$20.20+0.5%$15.60$8.89▼$24.50$878.09MN/A558,901 shs539,151 shsELMDElectromed$24.47-1.8%$20.16$16.58▼$35.56$207.98M0.5483,934 shs87,111 shsSIBNSiBone$16.29-0.4%$16.88$11.70▼$20.05$702.77M0.81326,750 shs240,114 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+3.77%-0.99%+16.22%+46.34%+22.36%BBNXBeta Bionics+0.50%+7.22%+32.89%+5.87%+2,019,999,900.00%ELMDElectromed-1.77%-1.05%+32.77%+16.80%+46.70%SIBNSiBone-0.37%-2.28%-0.73%-13.81%+0.18%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$26.0062.70% UpsideBBNXBeta Bionics 2.75Moderate Buy$22.5611.66% UpsideELMDElectromed 3.33Buy$36.2548.14% UpsideSIBNSiBone 3.00Buy$23.6745.28% UpsideCurrent Analyst Ratings BreakdownLatest ELMD, BBNX, AXGN, and SIBN Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails8/27/2025ELMDElectromedLoop CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$36.008/27/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$29.00 ➝ $35.008/27/2025ELMDElectromedLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$36.008/11/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetOverweight$25.008/5/2025SIBNSiBoneCantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$25.007/30/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$18.00 ➝ $21.007/30/2025BBNXBeta BionicsRobert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price TargetNeutral$15.00 ➝ $17.007/22/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$29.007/21/2025ELMDElectromedRoth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy6/16/2025BBNXBeta BionicsTruist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$26.006/12/2025BBNXBeta BionicsLake Street CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$30.00(Data available from 9/6/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M3.92N/AN/A$2.36 per share6.77BBNXBeta Bionics$65.12M13.48N/AN/A($5.72) per share-3.53ELMDElectromed$64M3.19$0.59 per share41.36$5.10 per share4.80SIBNSiBone$185.26M3.79N/AN/A$3.98 per share4.09Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.10N/AN/AN/A-2.29%-4.43%-2.34%11/6/2025 (Estimated)BBNXBeta Bionics-$54.76MN/A0.00∞N/AN/AN/AN/AN/AELMDElectromed$5.15M$0.8432.63∞N/A11.34%15.71%13.37%N/ASIBNSiBone-$30.91M-$0.56N/AN/AN/A-12.83%-14.20%-10.38%11/11/2025 (Estimated)Latest ELMD, BBNX, AXGN, and SIBN EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/4/2025Q2 2025SIBNSiBone-$0.19-$0.14+$0.05-$0.14$48.12 million$48.63 million7/29/2025Q2 2025BBNXBeta Bionics-$0.51-$0.39+$0.12-$0.39$19.73 million$23.24 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ABBNXBeta BionicsN/AN/AN/AN/AN/AELMDElectromedN/AN/AN/AN/AN/ASIBNSiBoneN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.594.142.67BBNXBeta BionicsN/A14.6813.79ELMDElectromedN/A5.104.74SIBNSiBone0.218.387.00Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%BBNXBeta BionicsN/AELMDElectromed40.82%SIBNSiBone98.11%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%BBNXBeta BionicsN/AELMDElectromed14.00%SIBNSiBone4.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45046.01 million44.73 millionOptionableBBNXBeta Bionics29443.47 millionN/AN/AELMDElectromed1608.35 million7.36 millionOptionableSIBNSiBone35043.14 million41.42 millionOptionableELMD, BBNX, AXGN, and SIBN HeadlinesRecent News About These CompaniesFirst Light Asset Management LLC Acquires 475,426 Shares of SiBone $SIBNSeptember 4 at 7:27 AM | marketbeat.comParadigm Capital Management Inc. NY Trims Stock Holdings in SiBone $SIBNSeptember 2, 2025 | marketbeat.comWalleye Capital LLC Buys Shares of 80,910 SiBone $SIBNSeptember 2, 2025 | marketbeat.comChamplain Investment Partners LLC Decreases Stake in SiBone $SIBNAugust 30, 2025 | marketbeat.comVanguard Group Inc. Increases Holdings in SiBone $SIBNAugust 29, 2025 | marketbeat.comAlphaQuest LLC Purchases 25,764 Shares of SiBone $SIBNAugust 28, 2025 | marketbeat.comRussell Investments Group Ltd. Has $2.83 Million Stake in SiBone $SIBNAugust 27, 2025 | marketbeat.comSI-BONE to Present at Morgan Stanley 23rd Global Healthcare Conference on September 9, 2025August 26, 2025 | globenewswire.comAmerican Century Companies Inc. Purchases 264,254 Shares of SiBone $SIBNAugust 23, 2025 | marketbeat.com1,326,100 Shares in SiBone $SIBN Acquired by Nuveen LLCAugust 22, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) SVP Sells $52,065.56 in StockAugust 21, 2025 | insidertrades.comTocqueville Asset Management L.P. Has $3.58 Million Stake in SiBone (NASDAQ:SIBN)August 19, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Director John Gordon Freund Sells 12,132 SharesAugust 12, 2025 | marketbeat.comInsider Selling: SiBone (NASDAQ:SIBN) Director Sells 12,132 Shares of StockAugust 12, 2025 | insidertrades.comSiBone (NASDAQ:SIBN) Stock Rating Lowered by Wall Street ZenAugust 10, 2025 | marketbeat.comFY2025 EPS Estimates for SiBone Boosted by Cantor FitzgeraldAugust 9, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Shares Down 13.1% - Here's What HappenedAugust 6, 2025 | marketbeat.comSiBone (NASDAQ:SIBN) Earns "Overweight" Rating from Cantor FitzgeraldAugust 6, 2025 | marketbeat.comSI-Bone Reports Strong Q2 2025 Financial ResultsAugust 5, 2025 | msn.comSI-BONE, Inc. (SIBN) Q2 2025 Earnings Call TranscriptAugust 5, 2025 | seekingalpha.comSI-BONE, Inc. 2025 Q2 - Results - Earnings Call PresentationAugust 4, 2025 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeELMD, BBNX, AXGN, and SIBN Company DescriptionsAxoGen NASDAQ:AXGN$15.98 +0.58 (+3.77%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$16.05 +0.07 (+0.44%) As of 09/5/2025 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Beta Bionics NASDAQ:BBNX$20.20 +0.10 (+0.50%) As of 09/5/2025 04:00 PM EasternBeta Bionics, Inc. is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.Electromed NYSE:ELMD$24.47 -0.44 (-1.77%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$24.41 -0.06 (-0.25%) As of 09/5/2025 05:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Electromed, Inc. develops, manufactures, markets, and sells airway clearance therapy and related products that apply high frequency chest wall oscillation (HFCWO) therapy in pulmonary care for patients of various ages in the United States and internationally. The company offers SmartVest airway clearance system for patients with compromised pulmonary functions, including bronchiectasis and cystic fibrosis, as well as neuromuscular conditions, such as cerebral palsy and amyotrophic lateral sclerosis; SmartVest SQL System; SmartVest Clearway System that consists of an inflatable therapy garment, a programmable air pulse generator, and a patented single-hose that delivers air pulses from the generator to the garment to create oscillatory pressure on the chest wall; and SmartVest Connect, a wireless technology that allows data connection between physicians and patients to track therapy performance and collaborate in treatment decisions. It also provides single patient use SmartVest and SmartVest Wrap products for health care providers in the acute care setting. The company offers its products to hospitals, home health care centers, pulmonary rehabilitation centers, cystic fibrosis centers, neuromuscular clinics, and other clinics through distributors. It markets its products to physicians, health care providers, and directly to patients. Electromed, Inc. was incorporated in 1992 and is headquartered in New Prague, Minnesota.SiBone NASDAQ:SIBN$16.29 -0.06 (-0.37%) Closing price 09/5/2025 04:00 PM EasternExtended Trading$16.30 +0.01 (+0.06%) As of 09/5/2025 05:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.SI-BONE, Inc., a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products. The company also provides iFuse-3D, a titanium implant that combines the triangular cross-section of the iFuse implant with the proprietary 3D-printed porous surface and fenestrated design; iFuse-TORQ, a set of 3D-printed threaded implants designed to treat pelvic trauma; and iFuse Bedrock Granite implant provides sacroiliac fusion and sacropelvic fixation as a foundational element for segmental spinal fusion. It markets its products primarily with a direct sales force, as well as through agents and resellers. SI-BONE, Inc. was incorporated in 2008 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/01 - 09/05 Lululemon Share Price Has Plenty of Room Left to Fall Why DocuSign Could Be a SaaS Value Play After Q2 Earnings Why Hedge Fund Elliott Bet $4B on Pepsi and Sees Over 50% Upside Palantir Insider Selling: Risk Signal or Normal Activity? Advanced Micro Devices' 2026 Forecasts Are Way Too Low Salesforce Stumbles, But Investors Eye a Major Comeback Buy the Dip? GitLab’s Bullish Case Outweighs the Bears Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
